emphasi outcom effici shift
basi competit med-tech
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
valuat growth profit
methodolog valu compani
acquisit covidien produc combin
compani forc reckon med-tech
wide rang chronic diseas covidien breadth
product acut care hospit bolster
posit key partner hospit custom
histor focus design manufactur
devic address cardiac care neurolog spinal condit
diabet along firm remain focus
fundament strategi innov often first market
new product invest heavili intern research
develop effort well acquir emerg
technolog howev post-reform healthcar world
higher hurdl secur reimburs
next-gener technolog slightli shift
strategi focu partner close hospit client
offer greater breadth product servic help
hospit oper effici partner close
integr hospit oper think
firm well posit take advantag busi
opportun value-bas reimburs environ
alway appreci divers portfolio
certain wane product line would off-set growth
categori addit devic consum use
surgic suit stabil potenti speed bump
individu product line continu focu
gener roughli billion chines sale fiscal
broad portfolio product fit well
firm earlier purchas kanghui hold provid
firm establish network nativ distributor
reach thousand hospit china
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest medic devic compani develop
manufactur therapeut medic devic chronic diseas portfolio
spinal fixat devic neurovascular product surgic tool
compani market product healthcar institut physician
unit state oversea foreign sale account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit
moder rais fair valu estim
per share reflect optimist
expect innov cardiovascular diabet
neurovascular unit well increment margin
expans follow sale legaci covidien medic
suppli busi
shed busi project
averag annual top-lin growth remain
product line incorpor lukewarm growth
cardiac rhythm manag declin
spine
howev expect new neuromodul
indic drug-elut balloon insulin pump
on-going develop atrial fibril market
corevalv sale defend price eros near
revenu growth restor therapi group
fiscal driven resumpt healthcar
util adopt new technolog
neuromodul neurovascular
legaci gross margin histor
held firm addit covidien lower
roughli basi point anticip
compani eke increment improv
next five year firm ration manufactur
asset project normal gross margin closer
longer term expect cost synergi
emerg sale administr thank
cross-sel bundl product servic
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
base case assum see
low-single-digit growth busi concern
overus dampen sale off-set strength atrial
fibril endovascular structur heart surgic
technolog expect spinal devic infus
regain double-digit growth seen howev
biggest wild card quickli
introduc meaning innov support
favor clinic evid magnitud product
pull-through emerg new partnership
outsourc agreement forg
hospit client firm new product surpris us
upsid increment product revenu associ
servic agreement exceed expect
firm lower manufactur cost wring
administr save expect next
year fair valu estim would rise
hand cardiovascular divis remain
mire low-single-digit growth indic expans
corevalv fail spine fall expect
product pull-through emerg fair valu
estim would fall per share
wide moat root domin presenc
highli engin medic devic treat chronic
diseas includ beyond histor stronghold
heart diseas moat come sever
cardiac area compet roughli three
competitor total across heart-rel portfolio
market pacemak icd coronari stent heart valv
neuromodul gener oper
spine area moat strengthen high
switch cost surgeon doctor often reli medic
devic sale rep deep devic knowledg well
experi devic usag wide rang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
develop approv process particular new
devic invest neuromodul diabet
spinal product middl late paid
spade although spine
busi hit slower market growth sinc
firm seen double-digit growth diabet
atrial fibril segment
product line wane new clinic data alter
treatment guidelin firm continu invest
emerg technolog drive futur growth
addit covidien deepen competit
advantag covidien medic devic segment enjoy
brand recognit technolog innov substanti
record enhanc
increment research invest past year
result steadi stream product upgrad
new technolog covidien devic subseg
oper oligopolist fashion absenc irrat
price competit evolutionari
rather
revolutionari natur innov tend lead
margin share shift industri strong excess
return covidien current rank near top
product categori compet devic vie
mainli johnson johnson rest field
fragment compani
occupi product nich rather compet broadli
big two
seen new entrant make signific inroad
new competitor sometim pop margin rang
less sophist discount price high-end
technolog advanc rare result
defens practition rare switch
competitor product inertia well
up-front train cost surgeon influenc
procur decis arguabl wane establish
patient result rep play role highli
special expert advis practition
implant program mainten medtron
devic creat sticki relationship medic
practition dynam tend keep spinal surgeon
loyal product long compani
fall far behind competitor come
final wide moat bolster sever
intang includ intellectu properti care
nurtur relationship physician thank
persist abil innov often first
market new product variou therapeut area
expect continu record innov base
extens patent portfolio accord independ
patent board hold strongest
intellectu properti posit base number
technolog strength patent
portfolio allow better weather occasion glitch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
player also administr ear covidien
domin number surgic specialti breadth
portfolio render competitor effort displac
cost individu product basi less meaning
moat remain stabl partli thank stabl
oligopoli compet primarili
abbott purchas st jude medic edward
lifesci cardiac devic johnson
johnson hospital-ori surgic devic tool
competitor may trade market share point
sever year rel short product cycl allow
peer regain share fairli quickli
consist control cardiac rhythm
manag market also domin competitor
structur heart neuromodul insulin pump
firm continu innov intern well purchas
new complementari technolog remain
forefront medic devic
wake healthcar reform doctor sign
employe healthcar provid think shift
realign doctor financi interest
hospit practic group howev note medtron
alreadi maneuv better posit partner
hospit healthcar system doctor see
influenc wane wide-rang product portfolio
particularli suit play role way
competitor introduc servic
wrap around devic
new hospit solut servic taken
big step new role manag catheter
electrophysiolog lab deliv oper
effici think hospit could seek firm
servic turn closer integr
servic hospit oper could also rais
switch cost hospit custom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
histor held roughli share
core heart devic also market leader
spinal product insulin pump neuromodul
chronic pain
pipelin attract treatment
fibril aortic stenosi variou
neurolog disord new therapi prove
effect could domin three
often find novel way appli familiar
technolog like use implant electron
pacemak
incontin chronic pain
address
technolog may face stiffer fight
maintain leadership arena
devic indirectli subject medicar
increas pressur
oover year issu number
voluntari recal product although
fatal associ problem
effort hurt doctor confid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
financi health deterior somewhat
financ signific portion covidien merger
new debt issuanc covidien sharehold own
combin entiti time merger
allow combin entiti invert covidien irish
domicil lower tax rate enhanc abil
access oversea cash end januari
owe billion debt around time
adjust ebitda around time
histor sinc firm paid roughli
billion debt plan de-lever near
futur upon sale legaci covidien medic suppli
portfolio think medtron easili
shoulder current debt load beyond debt oblig
firm aim return minimum annual free
cash flow sharehold shoot
dividend pay-out ratio consist engag share
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
babi boomer hit medicar age could futur
cut medicar reimburs device-rel
procedur innov name game medic
devic bar rais wake
healthcar reform success secur price premium
new technolog longer given depend
favor clinic data increas regulatori attent
interest conduct extens clinic trial
aftermarket studi could increas develop cost
product recal liabil inventori
write-down occasion sore spot industri
although depart justic wrap
investig off-label use infus product without
issu charg
controversi around
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
investig ad uncertainti contribut declin
infus sale potenti investig product
market remain risk medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
fidel manag research compani
share
fund
share
fund
omar ishrak left lead
ceo chairman ishrak littl direct
experi cardiac market devic industri
consid rise star ge ishrak pioneer
behind success entranc china
market -- led effort expand product portfolio
order compet head head local chines imag
compani mindray gave ge substanti
leg midmarket china consid
make number invest china
india identifi emerg market strateg
sourc growth think
perspect parti think push medtron
away -centric past focus organ
close potenti emerg market
moreov drive forc behind
earli effort posit new product servic help
hospit custom improv outcom lower cost -- key
prioriti shift hospit purchas behavior
wake afford act
manag capital-alloc decis
primarili solid occasion misstep come
acquisit like major medic devic
compani make regular acquisit
smaller often privat held firm offer emerg
technolog purchas typic dilut
short term technolog still requir much
develop reach commerci though
difficult assess valu purchas
tend view invest akin intern
invest must make main
concern even though seen
pattern goodwil impair hesit poni
gener offer certain acquisit target
seem add valu longer term exampl
spent billion purchas kyphon
acquisit turn disappoint
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fewer-than-expect synergi term sale
market physician relationship unfortun
abl goos kyphon product
back robust growth howev think mani
acquisit add valu time
includ corevalv cryocath covidien
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
medtron see strong perform fve
follow medtron strong fiscal third-quart result
small adjust immateri fair valu
estim compar quarterli top-lin growth
constant currenc gener broad-bas thank
adopt new product coronari structur heart
advanc energi stapl diabet manufactur
cost slightli lower expect off-set
slightli higher sell administr expens
medtron impress execut on-going effort
take advantag new value-bas opportun
underscor confid firm wide econom
two aspect quarter particularli
noteworthi perspect first manag
comment guardian connect continu glucos
monitor lead us believ readi put
muscl behind market stand-alon product
avail stand-alon basi
medtron focu
medtron cgm offer individu predict alert
tap big data analyt watson weve
discuss though sensor trail
accuraci begun compet
meaning featur benefit see latest
effort anoth way leverag major
competit advantag diabetesit data collect
analysi lead better predict algorithm
second pioneer way benefit
shift value-bas reimburs risk-bas
contract exampl roughli devic
type contract contribut
signific sale tyrx anti-infect envelop
tyrx establish separ reimburs
hospit will pay extra knowledg
pay treatment patient
come device-rel infect
think kind risk-bas contract gain steam
hospit seek reduc financi risk
associ patient complic
well-posit partner custom type
situat firm alreadi begun launch type
risk-bas program includ repeat target lesion
procedur patient use drug-coat
balloon rehospit patient use
cardiac resynchron technolog
aggress pilot approach appli
technolog portfolio
medtron set benefit new wax product
cycl chang fve
wide-moat post second-quart result
demonstr strength underli demand
product firm abil roll innov product
despit unexpect speed bump hurrican damag
manufactur facil firm remain track
meet full-year project leav fair
valu estim unchang remain fan medtron
wide econom moat saw evid second
grew fuel structur heart neurovascular
partial off-set soft pain therapi spine
typic wax product cycl tend
compens wane product
medtron impend new product introduct
recent approv devic help sustain growth
near term close gap
competitor exampl next-gener corevalv
evolut offer significantli reduc rate conduct
abnorm follow procedur -- issu
requir patient pacemak
implant latest transcathet valv still
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
match edward lifesci sapien arrhythmia
evolut within strike distanc rival
continu keep eye emerg competit
mri-saf
still acceler
anticip market share would erod
peripheri howev posit held better
expect far
pleas see suppli issu continu
glucos monitor sensor address adequ
suppli sight give us confid diabet
revenu rise high-single-digit growth fiscal
potenti upsid rival
johnson johnson direct anima pump user
final reassur commerci
intelli spinal cord stimul relief chronic pain
provid news around pain
franchis keep fall far behind competit
product meaning innov
take place pain devic market includ legaci
st jude part abbott variabl stimul
intend quiet breakthrough pain high-
frequenc therapi risk
leadership posit spinal cord stimul pain
manag nibbl away although skeptic
intelli efficaci next-gen rival simpli
launch next-gen product still help
thank diversif expans reach
hospit isnt necessari compani
alway launch meaning innov everi product
categori privileg come wide
econom moat long doesnt fall far
behind peer still press formid competitor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end april
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end april
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
